SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In ...
The causative agent of the coronavirus disease 2019 (COVID-19) – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – was first detected in Wuhan, China, in December 2019. To date, the virus ...
In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of ...
Gene delivery vehicles have helped realize the concept of treating human diseases by introducing normal alleles of genes into appropriate target cells. These gene delivery vehicles include recombinant ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
Recombinant Adeno-associated virus (rAAV) is the viral vector of choice for many ground-breaking research and clinical applications. The vector is being utilized in gene therapy to treat rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback